Heart Failure

The AJMC^® Heart Failure compendium is a comprehensive resource for clinical news and expert insights for the chronic condition in which the heart doesn't pump enough blood due to damaged heart muscle.

Latest News

Carpal tunnel syndrome may prove to be a potential indicator for cardiac amyloidosis. | Image Credit: bluebay2014-stock.adobe.com

Carpal Tunnel Syndrome Linked to Cardiac Amyloidosis

By Sabrina McCrear

July 17th 2025

Carpal tunnel syndrome was linked to wild-type transthyretin amyloidosis in new research, highlighting the importance of early diagnosis for better heart failure outcomes.

The approval was based on results from the phase 3 FINEARTS-HF trial. | Image Credit: aznan - stock.adobe.com

FDA Approves Finerenone for Heart Failure With Mildly Reduced or Preserved LVEF

By Rose McNulty

July 14th 2025

Dallas Texas | Image Credit: © SeanPavonePhoto - stock.adobe.com

Value-Based Care Is Key to Bringing Cardiology Breakthroughs to Those Who Will Benefit Most

By Christina Mattina

March 13th 2025

Phoenix Arizona | Image Credit: © Kevin Ruck - stock.adobe.com

Closing the Gaps in Cardiac Care With Technology, Collaboration

By Christina Mattina

March 12th 2025

the top 5 heart failure content of 2024

Top 5 Most-Read Heart Failure Articles of 2024

By Hayden E. Klein

December 23rd 2024

Continuing Medical Education

July 17th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

July 17th 2025

Evidence-Based Guidelines Point to Leap in Care for Hypertrophic Cardiomyopathy

1.0 Credit / Cardiology

July 17th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

July 17th 2025

Driving Better Outcomes in Hypertrophic Cardiomyopathy: A Managed Care Imperative

1.5 Credits / Cardiology

July 17th 2025

The Evolving Landscape of Transthyretin Amyloidosis Cardiomyopathy: New Therapies and Treatment Strategies

1.5 Credits / Cardiology, Rare Diseases

July 17th 2025

Pulmonary Arterial Hypertension: Real-World Applications of New Therapies and Management Strategies

1.5 Credits / Pulmonology, Cardiology, Rare Diseases

More News

Researchers Find Possible Treatment Target for Heart Failure

November 4th 2019

Researchers Find Possible Treatment Target for Heart Failure

Researchers at the University of Alabama at Birmingham first isolated the kinase HIPK2 from among hundreds of potential targets by using bioinformatics to hone in on the protein kinase as a target for study.

What We're Reading: Number of Uninsured Children Soars; Heart Failure Deaths Rise; Alabama Abortion Ban Halted

October 30th 2019

What We're Reading: Number of Uninsured Children Soars; Heart Failure Deaths Rise; Alabama Abortion Ban Halted

The number of uninsured children in the United States rose by more than 400,000 between 2016 and 2018 and now stands at over 4 million; mortality from heart failure rose 20.7% between 2011 and 2017 and is likely to keep climbing sharply; US District Judge Myron Thompson issued a preliminary injunction temporarily blocking Alabama from enforcing a near-total abortion ban.

FDA Approves Dapagliflozin to Cut Risk of Hospitalization for Heart Failure in Type 2 Diabetes

October 21st 2019

FDA Approves Dapagliflozin to Cut Risk of Hospitalization for Heart Failure in Type 2 Diabetes

Results are based on the DECLARE-TIMI 58 cardiovascular outcomes trial, presented last year at the American Heart Association Scientific Sessions.

FDA Approves Canagliflozin to Prevent Kidney Failure, Hospitalization for Heart Failure

October 1st 2019

FDA Approves Canagliflozin to Prevent Kidney Failure, Hospitalization for Heart Failure

The new indication is based on results of the CREDENCE trial, which found that canagliflozin reduced the risk of renal failure or death by 30% in those that had both type 2 diabetes and diabetic kidney disease.

This Week in Managed Care: September 20, 2019

September 20th 2019

This Week in Managed Care: September 20, 2019

This week, the top managed care stories included Purdue Pharma filing for bankruptcy; new data showing the number of people who get screened for HIV at least once falls far short of what CDC recommends; findings that most US hospital markets are now highly concentrated.

What We're Reading: Fast Track Designation for Dapagliflozin; California Advocates Against Vaping; Measles Cases Fading

September 17th 2019

What We're Reading: Fast Track Designation for Dapagliflozin; California Advocates Against Vaping; Measles Cases Fading

The FDA grants fast track designation of AstraZeneca's dapagliflozin; California to conduct public awareness campaign against vaping; no new US measles cases.

This Week in Managed Care: September 6, 2019

September 6th 2019

This Week in Managed Care: September 6, 2019

This week, the top managed care news included a diabetes drug showing positive results in treating heart failure; new lipid guidelines promoting the use of proprotein convertase subtilisin/kexin type 9 inhibitors; and a study finding doctors are more likely to prescribe opioids if they are in a hurry.

5 Things to Look for at the European Society of Cardiology 2019 Congress

August 23rd 2019

5 Things to Look for at the European Society of Cardiology 2019 Congress

Studies on anticoagulants and SGLT2 inhibitors, and guidelines for dyslipidemia and more are anticipated at the meeting.

This Week in Managed Care: August 23, 2019

August 23rd 2019

This Week in Managed Care: August 23, 2019

This week in managed care, the top news included outcomes results in treating heart failure; US prevention experts said more women should get BRCA testing; the American Heart Association offered an advisory on treating high triglycerides with prescription omega-3 fatty acids.

AstraZeneca's Dapagliflozin Meets Primary End Point in Heart Failure Trial

August 20th 2019

AstraZeneca's Dapagliflozin Meets Primary End Point in Heart Failure Trial

Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure includes patients with and without type 2 diabetes, although the topline results did not specify if results were similar in these 2 populations.

June 29th 2019

AstraZeneca's Khan Discusses Dapagliflozin and Cardiovascular, Renal Outcomes in Diabetes Care

A discussion with Naeem Khan, MD, vice president of US cardiovascular and metabolic diseases at AstraZeneca, on lessons from the wave of cardiovascular outcomes trials, the new focus on renal outcomes, and what’s next for SGLT2 inhibitors.

FDA's Fast Track Designation for Empagliflozin in Heart Failure Points to New Paradigm

June 28th 2019

FDA's Fast Track Designation for Empagliflozin in Heart Failure Points to New Paradigm

The EMPEROR trials could lead to new indications for the SGLT2 inhibitor for patients with and without diabetes.

This Week in Managed Care: May 10, 2019

May 10th 2019

This Week in Managed Care: May 10, 2019

This week, the top managed care news included HHS announcing a finalized rule requiring the disclosure of drug prices in television ads; a report finding high satisfaction with employer health coverage despite the cost; a study finding heart failure is surging among young adults.

What We're Reading: Medicaid Fraud Settlement; Heart Failure in Young Adults; FDA Investigates Sunscreen

May 7th 2019

What We're Reading: Medicaid Fraud Settlement; Heart Failure in Young Adults; FDA Investigates Sunscreen

Federal prosecutors have reached a $17 million settlement with Acadia after Medicaid fraud allegations; rates of heart failure–related deaths are on the rise among adults between 35 and 64 years old; the FDA has asked manufacturers of sunscreen to review the safety of the chemicals used in their products after a new study found that many of the ingredients in sunscreen may be absorbed into the bloodstream upon use.

5 Takeaways From the 2019 American College of Cardiology Meeting

March 22nd 2019

5 Takeaways From the 2019 American College of Cardiology Meeting

For SGLT2 inhibitors and a fish oil capsule, there was plenty of good news; for aspirin, not so much. A recap of the American College of Cardiology's 68th Annual Scientific Session, held March 16-18, 2019, in New Orleans, Louisiana.

March 18th 2019

Relationship Between Heart Failure and Diabetes Seen Throughout ACC Sessions

More than a decade after an FDA mandate for cardiovascular outcomes trials, cardiologists say insights gained on how 2 new drug classes affect heart failure in diabetes should be used to prevent complications. Several sessions at the 68th Scientific Session of the American College of Cardiology addressed this topic.

March 17th 2019

Debate Over 30-Day Readmission Metric Dominates Quality Session

A session at the 68th American College of Cardiology Scientific Session continues the ongoing debate whether a CMS reimbursement model has contributed to rising mortality in patients with heart failure.

March 16th 2019

Giant Study Suggests Apple Watch Accurately Catches Atrial Fibrillation

The 68th American College of Cardiology Scientific Session and Exposition opens with a study that suggests the Apple Watch can detect atrial fibrillation with a reasonable degree of accuracy, giving people an opportunity to get in touch with their doctor before a serious event like a stroke.

From the Apple Watch to Heart Failure at Annual Cardiologists' Meeting

March 16th 2019

From the Apple Watch to Heart Failure at Annual Cardiologists' Meeting

In recent years, the big news on the first day of the American College of Cardiology (ACC) Scientific Session and Exposition has involved a therapy—usually an expensive cholesterol drug with a name almost no one could pronounce: proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. This year, it's tech, and an easy-to-pronounce name: Apple.

Diabetes Updates: Glucose From Siri, New Indication for Soliqua, More Recalls for Valsartan

March 2nd 2019

Diabetes Updates: Glucose From Siri, New Indication for Soliqua, More Recalls for Valsartan

A technology update, a new drug approval, and a drug recall due to more impurities.

New Analysis Finds Hope for Reducing Heart Failure

January 12th 2019

New Analysis Finds Hope for Reducing Heart Failure

The analysis discusses the strength of evidence that SGLT2 inhibitors have a class effect in preventing heart failure for patients with diabetes.

People Living With HIV Have 2-Fold Risk of Heart Failure

January 5th 2019

People Living With HIV Have 2-Fold Risk of Heart Failure

Jaime Rosenberg

People living with HIV are at a greater risk for incident heart failure, with those with higher viral loads and lower CD4+ T cell counts having the greatest risk.

COPD Increases Risk of Death in Patients With Heart Failure

December 22nd 2018

COPD Increases Risk of Death in Patients With Heart Failure

Allison Inserro

Increased severity of chronic obstructive pulmonary disease (COPD) was associated with an increased risk of mortality and hospitalization in patients with heart failure, according to a recent study published in JAMA Open.

Cardiovascular Results for Dapagliflozin Point to SGLT2 Use to Prevent Heart Failure

November 11th 2018

Cardiovascular Results for Dapagliflozin Point to SGLT2 Use to Prevent Heart Failure

Results presented at the American Heart Association in Chicago provided the strongest evidence to date on what heart failure specialists have discussed for several years now: the possibility that SGLT2 inhibitors might be used to prevent heart failure in patients with type 2 diabetes.

September 24th 2018

MitraClip Reduces Hospital Stays, Deaths Among Patients With Heart Failure

Heart failure hospitalization has been a target for accountable care organizations seeking to find ways to cut costs from the healthcare system. But it remains to be seen how many of the estimated 2 million patients would gain access to the device if it received an expanded indication and payer coverage.

August 30th 2018

How Michigan Hospitals Utilize Technology to Track and Target Heart Failure Care

Michigan Value Collaborative

Hospital participants shared how they have utilized technology to enhance care for heart failure patients. Below are some highlights of these resources and initiatives.

Collaborative Care Intervention Did Not Improve Health Status of Patients With Heart Failure

July 27th 2018

Collaborative Care Intervention Did Not Improve Health Status of Patients With Heart Failure

Samantha DiGrande

In a recent study, researchers looked to determine whether a symptom and psychosocial collaborative care intervention would improve heart failure–specific health status, depression, and symptom burden in patients with heart failure.

Dr Mary Norine Walsh on Who Is at High Risk for Peripartum Cardiomyopathy

June 21st 2018

Dr Mary Norine Walsh on Who Is at High Risk for Peripartum Cardiomyopathy

Mary Norine Walsh, MD, immediate past president of the American College of Cardiology, discusses the symptoms of peripartum cardiomyopathy, and who is at the highest risk for developing it.

April 23rd 2018

JAMA Comparison: SGLT2 Inhibitors, GLP-1 Agonists Offer Lower Mortality in Type 2 Diabetes

Guidance for primary care physicians prescribing type 2 diabetes therapies comes at an opportune time. A major rift over guidelines for glycemic control has opened between the American College of Physicians, a professional association of internists, and diabetes specialists, including endocrinologists and diabetes educators.

Medicare's Reliance on 3 Conditions to Calculate Quality, Penalties Called "Incomplete" by Study

March 27th 2018

Medicare's Reliance on 3 Conditions to Calculate Quality, Penalties Called "Incomplete" by Study

Allison Inserro

Condition-specific readmissions measures for heart failure, pneumonia, and heart attack may not accurately or fairly reflect hospital quality, according to a study published this week in the Annals of Internal Medicine. The study found significant differences in hospitals' performance when readmissions were assessed for non-Medicare patients and for conditions other than those currently reported, showing that when these additional factors are taken into account, half of the hospitals would be subject to a change in their financial penalty status.

...

12 13 14 15 16 17 18 19 20 21 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions